Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies

TL;DR

A patient with advanced ovarian clear cell carcinoma responded well to targeted therapies after standard treatments failed.

Contribution

Demonstrates successful use of alpelisib and immunotherapy in treating resistant ovarian clear cell carcinoma.

Findings

Alpelisib provided a durable response based on genomic testing.

Nivolumab and ipilimumab combination showed partial response after alpelisib progression.

Targeted therapies offer promising options for advanced ovarian clear cell carcinoma.

Abstract

Background: Advanced stages of ovarian clear cell carcinoma have poorer prognoses than many other ovarian cancers. When standard treatments are ineffective, alternative options are needed.

Case: A 56-year-old woman was diagnosed with ovarian clear cell carcinoma and treated with surgical management as well as carboplatin and paclitaxel. At recurrence, her disease progressed despite multiple chemotherapy regimens. A durable response was achieved first with alpelisib, chosen based on genomic testing. When progression occurred on this agent, a partial disease response was achieved with the combination of nivolumab and ipilimumab.

Conclusion: The use of targeted therapies as well as the combination of nivolumab and ipilimumab is a promising option in advanced and recurrent cases of ovarian clear cell carcinoma.

Figures